Post-translational and co-translational enzymatic addition of glycans (glycosylation) to proteins, lipids, and other carbohydrates, is a powerful regulator of the molecular machinery involved in cell cycle, adhesion, invasion, and signal transduction, and is usually seen in both in vivo and in vitro cancer models. Glycosyltransferases can alter the glycosylation pattern of normal cells, subsequently leading to the establishment and progression of several diseases, including cancer. Furthermore, a growing amount of research has shown that different oxygen tensions, mainly hypoxia, leads to a markedly altered glycosylation, resulting in altered glycanreceptor interactions. Alteration of intracellular glucose metabolism, from aerobic cellular respiration to anaerobic glycolysis, inhibition of integrin 3α1β translocation to the plasma membrane, decreased 1,2-fucosylation of cell-surface glycans, and galectin overexpression are some consequences of the hypoxic tumor microenvironment. Additionally, increased expression of gangliosides carrying N-glycolyl sialic acid can also be significantly affected by hypoxia. For all these reasons, it is possible to realize that hypoxia strongly alters glycobiologic events within tumors, leading to changes in their behavior. This review aims to analyze the complexity and importance of glycoconjugates and their molecular interaction network in the hypoxic context of many solid tumors.
Glycobiology Modifications in Intratumoral
hepatocytes, and hepatoma cells [50] . These authors demonstrated that glycogen synthase 1 (GYS1), through HIF-1, together with upregulation of UTP enzymes (glucose-1-phosphate uridylyltransferase (UGP2) and 1,4-α glucan branching (GBE1) was related to hypoxiainduced glycogen metabolism [50] . Thus, this energy reserve can be accessed by tumor cells in situations of nutritional deprivation. Shen et al. exposed human MCF-7 cells to 24 or 48 h of hypoxia incubation (1% O 2 ) [51] . They found that the protein phosphatase 1 regulatory subunit 3C gene (PPP1R3C), also regulated by HIF-1, allows glycogen accumulation through activation of glycogen synthase, and a limitation of glycogen breakdown through reduction in glycogen phosphorylase activity [51] . Pelletier and collaborators (2012) demonstrated that mRNA and protein levels of the first enzyme of glycogenesis, phosphoglucomutase1 (PGM1), were increased in many lineages of cancer cells (human colon carcinoma LS174, human breast carcinoma MCF-7 and MDA-MB231, and human renal clear cell carcinoma RCC4 cells) under hypoxia [52] . While hypoxia regulates glycolytic flux in various tumors, glycolytic influence on hypoxic components was demonstrated by Liu et al., who cultured two pancreatic cancer lines under hypoxic conditions (6 h) in media with different glucose concentrations and 1% O 2 [53] . One lineage was HIF-1α inhibited and other expressed the transcription factor only in hypoxia. The authors found that glucose excess (16.7-22.2 mM) stimulated HIF-1α production in hypoxia-sensitive lineages [53] . However, in a previous study with the same lineage (adenocarcinoma cell line Mia PaCa-2), Kwon and Lee (2005) noted that HIF-1α expression was increased in hypoglycemic conditions but not in hyperglycemic conditions (8 h under hypoxia and 0.1% O 2 ) [54] . As indicated by the first author, the time of hypoxia exposition and oxygen concentrations were different, which may have influenced HIF-1α expression, reaffirming the results [54] .
Just as with the Warburg effect, the Pasteur effect was promoted to ensure a favorable metabolic reprogramming of tumor progression. The Pasteur effect represents the increase of glycolytic flux in response to negative feedback caused by allosteric effectors (glucose- Fig. 1 . Reprogramming of the carbohydrate metabolism in tumor cells under hypoxia. Loss of RAS and VHL and PI3K/AKT activation increases HIF1α expression. HIF1α, in turn, stops the tricarboxylic acid cycle and stimulates LDH, glucose and glutamine uptake, glycolysis, and pentose phosphate pathway. Ac-CoA-AcetylCoenzyme A; ASCT2-ASC aminoacid transporter 2; ASP-Asparate; CIT-Citrate;
Fru-1,6-P 2 -Frutose-1,6-biphosphate; Fru-2,6-P 2 -Frutose-2,6-biphosphate; Fru-6-PFrutose-6-Phosphate; FUM-Fumarate;
G6PD-Glucose-6-phosphate dehydrogenase; GLS-Glutaminase; Glu-6-P-Glucose-6-phosphate; HIF-1α-Hypoxia-induced factor alpha; HK-Hexokinase; LAT1-Amino acid transporter 1; LDHA-lactate dehydrogenase A; MAL-Malate; MCT1-Monocarboxylate transporter 1; MCT4-Monocarboxylate transporter 4; OAC-Oxaloacetate; PDH-pyruvate dehydrogenase; PDK1-Pyruvate dehydrogenase kinase 1; PFK1-6-phosphofructokinase 1; PFKFB3-6-phosphofructo-2-kinase/ fructose-2,6-biphosphatase 3; PI3K-phosphoinositide 3-kinase; PTEN-Phosphatase and tensin homologue; SUC-Succinate; VHL-von Hippel-Lindau; αKG-α-Ketoglutarate. 6 -phosphate (Glu-6-P), citrate, and ATP) over key glycolytic enzymes. This results in acceleration of glycolytic flux when the OXPHOS rate decreases, and, inversely, improving the link between glycolysis and OXPHOS fluxes when oxygen levels increase. In nascent tumors, cells distant of vascular supply must choose between hypoxic death and metabolic reprogramming. Due to the rapid need in ATP, the Pasteur effect is inhibited in these cells, but prolonged maintenance energy, mainly for more aggressive tumors, requires further adaptations to accelerate the glycolytic flux [55] [56] [57] .
In lung cancer cells (A549), Zhang et al. observed that the uptake of fluorodeoxyglucose (F-FDG), a glucose analogue, is increased in regions stained with pimonidazole, and is stimulated by nutritional deprivation, showing that metabolic utilization of glucose is higher in hypoxic and staring regions [58] . The Warburg and Pasteur effects were observed in diverse melanoma cells lines. Scott et al. showed that hypoxic conditions increased the fermentation of glucose into lactate, not only in melanoma cells, but also in melanocytes, emphasizing the importance of hypoxia to metabolic cell rewiring [56] .
Even though oxidative phosphorylation is more productive compared to glycolysis, the truth is that local availability of oxygen determines the majority of ATP synthesis of cells in the tumor microenvironment. However, molecular disorders caused by hypoxia affect not only specific points of the reactions responsible for the carbohydrates degradation and energy production. Formation of the glycidic portion in glycoconjugates, glycosylation, is affected by hypoxia both on surface and inside the tumor cells.
Hypoxia Regulates Glycosyltransferases, Glycosidases and Nucleotide Sugar Transporters Expression and Activity
Glycosylation is a phenomenon of molecular modification, in which the connections that leads to glycoconjugates are made and unmade by glycosyltransferases and glycosidases. Glycosyltransferases represent a very large family of enzymes that determine the biosynthesis of glycans by group-transfer reaction. In this reaction, the monosaccharide moiety of a simple nucleotide sugar donor substrate, such as UDP-Gal (Uridine diphosphate galactose), GDP-Fuc (Guanosine 5'-diphospho-fucose), or CMP-Sia (Cytidine 5'-monophospho-Nacetylneuraminic acid), is transferred to the acceptor substrate that includes oligosaccharides, monosaccharides, polypeptides, lipids, small organic molecules, and even DNA [59] . These enzymes, not only act in intracellular medium, but they also contribute to the glycosylation of cell surface receptors and extracellular matrix components, modulating signaling pathways and tumor behavior [60, 61] .
Modifications in glycosyltransferase and/or glycosidase expression, activity, and structure play a key role in the onset and progression of cancer, epithelial-mesenchymal transition (EMT), and metastasis [62] [63] [64] . These changes cause concomitant reconfiguration of the "glycocode" of tumor cells through fundamental processes in glycosylation, such as N-and O-glycosylation.
In cancer, glycosylation patterns can be altered by many factors, including changes in the expression levels of glycosidases and glycosyltransferases genes. This is due to loss of heterozygosity, a promoter methylation, and increase of gene expression or neoexpression [65] [66] [67] . Hypoxic microenvironments change the expression of glycosyltransferase genes, such as fucosyltransferases (FUTs), N-acetylglucosaminyltransferases (GnTs), and sialyltransferases (STs) [68] [69] [70] . The induction of a number of glycosyltransferase expressions by hypoxia induces tumor progression in various types of cancer, including colon, bile duct, bladder, gastric, and lung [68] [69] [70] [71] [72] [73] , as well as glycosidase gene expression [61, [74] [75] [76] .
The Mgat5 (mannosylglycoprotein N-acetyl-glucosaminyltransferase 5) gene encodes GnT-V, an enzyme that catalyzes the transfer of N-acetylglucosamine (GlcNAc) to α1,6-mannose in N-glycans to form a β1,6-branched N-glycan, thus elongating the polylactosamine structure. This molecule controls cell surface receptor position and is associated with some of the invasive characteristics of tumors [77] [78] [79] . GnT-V is regulated by Ets-1, a member x/a levels after seven days under hypoxic conditions [68] . Results were similar for cultures induced in a hypoxia chamber (1% O 2 ), and also using hypoxia mimetic desferoxamine. Under hypoxic conditions, cells also presented an enhancement of cell adhesion to endothelial E-selectin. In SW480 cells transfected with dominant-negative form of HIF, it was observed that there was a less pronounced increase of sialyl-Le a/x levels, indicating that HIF is directly involved in the induction process. After restoration of oxygen levels, the expression of sialyl Lewis a and x returned to basal levels [68] .
Glycosidases also participate in glycosylation reactions, removing monosaccharides to form intermediates, especially in the formation of N-glycans [87] . Aberrant sialylation is a characteristic feature of cancer cells, and has been proposed to be associated with malignant phenotypes, including invasiveness and metastatic potential [88] .
In a hypoxic tumor microenvironment, sialyl-Le a expression was up-regulated, accompanied by elevation of ST3Gal1 and FUT7. Shiozaki et al. found that hypoxia mimetic deferoxamine was capable to promote downregulation of NEU4S (a Human Sialidase Type) in HCT-15 colon cancer cells, which in turn favors ST3Gal1 activity to increase in sialyl-Le a levels [76] . Hypoxia-induced sialyl-Le x upregulation in SW-480 cells was also associated with the reduction of mRNA levels of NEU4S [76] . NEU4S catalyzes the removal of sialic acids, causing a reduction of cell attachment, cell migration, and cell proliferation, probably by lowering the binding of cancer cells to E-selectin in EC [60] . Therefore, NEU4S downregulation induced by hypoxia favors sialyl-Le a/x antigens upregulation, increasing a malignant phenotype (Fig. 3) . Heparanase (Hpa) activity and expression level significantly increased after exposure to hypoxia in pancreatic MIA PaCa-2 cancer cells, human ovarian cancer cell line (OC-MZ-6), and Hep-2 laryngeal carcinoma cell line [61, 74, 75] . This endo-β-glucuronidase catalyzes the cleavage of heparan sulfate (HS) side-chains, enhancing tumor cell invasion and migration, and releasing important HS-binding cytokines, relevant to angiogenesis, wound healing, and tumor growth [62] . The transfection of the Hpa gene into poorly metastatic cell lines is associated with a significant increase in metastasis in vivo, and clinical studies have correlated increased Hpa activity with invasion and poor prognosis [89] [90] [91] .
Studies have demonstrated that hyaluronic acid (HA), a polysaccharide component of the vessel basal membrane, is involved in the angiogenesis process [92] . The enzyme hyaluronidase (HAase) in lysosomes is responsible for HA degradation, digesting high molecular weight HA into low molecular weight HA (SMW) [93] . Chemical inducers of hypoxia (CoCl 2 and NaN 3 ) can upregulate the production of HA and HAase activity, resulting in a significant increase of SMW expression in T47D human breast cancer cells. Since SMW [94] . Hypoxia regulates glycosyltransferases and glycosidases expression in epithelial tumors, such as colon, pancreas, ovary, breast, prostate, and laryngeal carcinomas ( Table 1) . There are few reports regarding the influence of a hypoxic microenvironment in nucleotide sugar transporters expression. Further studies are necessary to understand the role of these molecules in tumors exposed to hypoxic conditions, since they play an important role in the glycosylation reaction.
Hypoxia Changes Membrane Glycoconjugates in Tumor Cells
The hypoxia microenvironment can affect the expression of different types of glycoconjugates, such as glycoproteins and glycolipids [68, 95, 96] . Some studies have reported molecular changes promoted by the hypoxia microenvironment, but did not elucidate the functional consequences promoted by glycoconjugates alterations in neoplastic cells. However, some studies associated these modifications with cancer cell proliferation, migration, and survival, indicating that such glycoconjugates may be used as targets for further therapeutic strategies for cancer treatment [97] [98] [99] .
Glycoproteins
Hypoxia can modulate the expression of various cell membrane glycoproteins. Among these we can highlight the Carbonic Anhydrase IX (CAIX) which play a central role in neoplastic cells adaptation to hypoxic microenvironment and mucins and integrins that are related to invasion and migration. HIF-1α can regulate the expression of CAIX, an N-linked transmembrane glycoprotein that is increased in malignant cells, including breast cancer [100, 101] . Ivanov and collaborators (2001), observed, using immunochemistry, the increased expression of CAIX in hypoxic regions of melanoma and breast carcinomas (Fig. 4 ) [102] . CAIX mRNA levels are also increased under hypoxic conditions in U87 glioblastoma cells [102] . In 2011, Li and collaborators observed that hypoxia promoted a significant increase of CAIX expression and activity in breast cancer cells (MDA-MB-231) [101] . Results of endoglycosidase H digestion assay showed that CAIX is present as a dimeric, high-mannose N-glycosylated protein. Such a structure is common in various types of cancer; however, it is atypical in normal cells [101] . Despite the current data, there are no studies that directly related the changes in CAIX glycosylation pattern promoted by hypoxia.
N-glycosylation is a well-characterized type of protein glycosylation and represents a vital process [103] . The N-glycosylation process follows coordinated steps that occur along the endoplasmic reticulum (ER) to Golgi, and its physiological functions include cellular mechanisms involved in cell-cell adhesion, cell motility, signal transduction, and hostpathogen recognition [3, 62, 104] . Changes in the N-glycosylation process can be related to oncogenesis and cancer progression. In fact, these structural changes are important in understanding the implications of the adhesive properties of cancer cells [105, 106] . A study performed by Ren et al. evaluated the effect of hypoxia on the integrin family in A431 epidermoid carcinoma cells [97] . Expressed glycoproteins were identified and quantified by iTRAQ (isobaric tags for relative and absolute quantitation) and liquid chromatography-mass spectrometry analysis. This author observed changes in integrin α-3 (ITGA3) levels, and its N-glycosylation, were inhibited by hypoxia. Other techniques (Western blotting, flow cytometry, immunofluorescence, and immunoprecipitation assays) showed that changes induced by hypoxia prevented ITGA3's efficient translocation to the plasma membrane. Mutagenesis studies indicated that lower levels of ITGA3 on the cell surface, such as hypoxia-induced levels, increase the invasiveness potential of cancer cells in vitro by blocking ITGA3's interaction with extracellular ligands (Fig. 4) [97] .
As in N-glycosylation, modifications in O-linked glycosylation are usual characteristics of malignant transformation in epithelial cells [98] . O-linked glycosylation is one of the most common post-translational mechanisms by which glycans are covalently linked to serine/ threonine residues [107, 108] . This process can occur in the Golgi, in the ER, or in the cytoplasm/nucleus [109, 110] . O-glycans are often classified as mucins and non-mucins.
Mucin type O-glycosylation is initiated by the α-linkage of N-acetylgalactosamine (GalNAc) moiety to the hydroxyl group of serine or threonine [110] . Formation of this c556omplex is catalyzed by GalNAc transferases, and the core α-GalNAc-Ser/Thr is called Tn antigen [111] . Subsequently, several glycosyltransferases are responsible for the elongation and termination of O-linked glycans, which usually includes galactose, GlcNAc, GalNAc, fucose, or sialic acid. Non-mucin O-glycans include α-attached via O-mannose, α-linked O-fucose, and the β-linked N-acetylglucosamine (O-GlcNAc) [112] . Small or truncated O-glycans are increased in different types of tumors, including gastric, colon, breast, and pancreatic cancer [113, 114] , and their production is associated with a poor prognosis and metastasis [115] .
Mucins constitute a family of glycoconjugates that are involved in epithelial cell homeostasis. Thus far, 21 mucins have been identified and can be found in membrane-bound or secreted forms [82] . Altered expression of mucins has been reported in several types of tumors, including gastrointestinal and breast cancer [116, 117] , and they have also been associated with hypoxic microenvironments.
Mucin 1 (MUC1) is a type I transmembrane protein, overexpressed in several cancer types, including pancreatic adenocarcinoma, and there is a known relationship between this protein and hypoxia. MUC1 regulates cancer cell metabolism, occupying the promoter elements of multiple genes involved in glucose metabolism in pancreatic cancer cells and stabilizes HIF-1α [99] . In contrast, in HTC116 colon cancer cells, MUC1 blocks hypoxiainduced stabilization of HIF-1α and consequently suppress ROS and hypoxia-induced apoptosis [118] . In human lung adenocarcinoma cell line, hypoxia increased MUC1 mRNA and protein levels via HIF-1α [94] . A similar pattern was shown in clear renal cell carcinomas. MUC1 is overexpressed in these renal carcinomas and a concomitant increase of MUC1 and HIF1-α in metastatic groups was observed. Furthermore, MUC1 expression under hypoxia is regulated by a HIF1-α-dependent mechanism, having effects on the migration properties of renal cancer cells [119] . MUC1 also participates in angiogenesis in AsPC1 pancreatic cancer cells. It has been shown that MUC1 is overexpressed in hypoxic conditions and stimulates proangiogenic factors VEGFA, PDGFB (Platelet Derived Growth Factor Subunit B), and CTGF (Connective Tissue Growth Factor) ( Fig. 5 ) [120] .
Other glycoproteins of the mucin family also present changes mediated by hypoxic conditions. Mucin 17 (MUC17) is a type I membrane-bound mucin that, under physiological conditions, plays an important role in colon-mucosal protection and cell restitution processes. MUC17 upregulation is associated with poor overall survival in pancreatic ductal adenocarcinoma [121] . Kitamoto et al. showed that MUC17 is significantly induced by hypoxia in a time-dependent manner in human pancreatic cancer cell lines (AsPC1 and HPAFII), and the induction is mediated by HIF1-α [122] . Since silencing of MUC17 gene in colon cancer cells was associated with reduced cell aggregation, cell-cell adherence, migration, and increased susceptibility to apoptosis [123] , MUC17 overexpression may be involved in cancer cell progression (Fig. 5) .
CD164 (or endolyn) is a type I integral transmembrane sialomucin that acts as a signaling receptor that regulates proliferation, adhesion, and migration in hematopoietic stem cells. This glycoprotein is also involved in the development of skeletal muscle [124] . In the tumor context, CD164 participates in the development of colorectal cancer and metastasis of prostate cancer cells to bone marrow. Tang et al. showed that hypoxia might be one factor responsible for CD164 upregulation in HCT 116 colorectal carcinoma cells, inducing tumor development (Fig. 5) [125] .
Glycolipids
Such as glycoproteins, glycolipids also change during malignant transformation, and these changes seem to be involved in the molecular mechanisms needed for early and late stages of carcinogenesis [126] [127] [128] . These changes are also affected by hypoxia, as demonstrated by Tanaka et al. in human colorectal cancer cells (Caco-2) under hypoxic conditions (O 2 1%) for three days [129] . The authors showed that, in normoxia, major constituent ceramide species of neutral glycosphingolipids (NGSLs) were composed of the usual long-chain base of sphingosine (d18:1) and hydroxy fatty acid (HFA); while, under hypoxic conditions, all the Cers, and nearly 80% of the sphingomyelins, were dihydrosphingolipids, composed of d18:0-NFAs, but a significant proportion of d18:1-HFAs still remained in the NGSLs [129] .
Gangliosides are acid glycosphingolipids that carry one or more residues of sialic acid, and are more abundant in the brain [127, 130] . Sialin, a gene for sialic acid transporter, is upregulated in colon cancer CaCo-2M cells and breast cancer ZR-75-1 cells submitted to hypoxic conditions, and is related to enhanced gangliosides carrying N-glycolyl sialic acid (NeuGc) [131] . Upregulation of sialin in hypoxic culture promotes the expression of NeuGc-GM2 (Ganglioside Monosialic 2) through an increase in the transport speed of sialic acid from external medium to cancer associated-ganglioside GM2. This results in a 
significant accumulation of unusual gangliosides carrying N-glycolyl sialic acid in cancers. Such gangliosides serve as surrogate markers for the presence of cell masses suffering from chronic hypoxia (Fig. 5 ) [131] . Cytidine Monophospho-N-Acetylneuraminic Acid (CMP-NeuAc)-hydroxylase oxidase is present in many mammals, but absent in humans, and is the enzyme responsible for de novo synthesis of N-glycolyl sialic acid through oxidative hydroxylation of N-acetyl sialic acid [128, 132] . Because it is an oxidative hydroxylation, this process, and the concomitant production of NeuGc through de novo synthesis, may be suppressed in hypoxic tissues in mammals that express CMP-NeuAc-hydroxylase. In contrast, the expression of NeuGc increases under hypoxic conditions in humans, where its level is determined by its salvaging through the transporter Sialin, instead of de novo synthesis [128] .
Another glycolipid is gangliotetraosylceramide (Gg4), which has important role in EMT process inhibition in human and mouse epithelial cells lines [133] . Pre-incubation with Gg4 can block the EMT process due to the strong linking capacity of Gg4 to E-cadherin and β-catenin, as evidenced by Guan et al. through immunoprecipitation. Under hypoxic conditions, normal murine mammary gland (NMuMG) showed reduced levels of Gg4, indicating a possible trend to EMT [134] .
Ganglioside GD3 has important role in the cell proapoptotic pathway, and it is known that GD3 reduces nuclear factor-kappa B (NF-κβ) levels, a molecule involved in the establishment of hypoxia [135] [136] [137] . Overexpression of GD3 synthase in human hepatocarcinoma cell line Hep3B sensitizes this cell line via hypoxia-induced ROS generation through its ability to suppress the tyrosine kinase cSrc/NF-kB survival pathway [138] , emerging as a therapeutic strategy to be studied. Hypoxic incubation of human colon cancer cell line LS174T promoted induction of GD3 expression and moderate induction of GM3.
Another factor that supports the use of gangliosides as therapeutic targets are the clinical successes recently achieved. The anti-idiotype vaccine targeting the NeuGcGM3 tumorassociated ganglioside in patients with advanced non-small cell lung cancer has proved to be effective and a well-tolerated treatment option [139] . Furthermore, FDA recently approved an antibody against disialoganglioside GD2 (dinutuximab) for neuroblastoma treatment [140] . However further studies are needed to evaluate the effects of these therapies in hypoxic microenvironment.
Increasing evidence about the functional role of glycolipids in a significant number of cellular physiological pathways has been consolidating the hypothesis that glycolipids participates on establishment of malignant cell behavior in hypoxia. Therefore, these glycoconjugates have a higher possible potential to serve as molecular therapeutic targets and clinical predictors in cancer.
Sialyl-Le x/a , which are expressed either protein-or lipid-bound on the cell surface, have their expression increased in different types of cancer, including gastric, colorectal, oral squamous cell, and pancreatic cancer [141] [142] [143] [144] . During the metastasis process, they act as carbohydrate ligands for E-selectin-mediated cancer cell adhesion [145] . Sialyl-Le a and Sialyl-Le x are found in CA19-9 and NCC-ST-439 clinical markers, respectively, and are used for monitoring cancer recurrence after surgery, especially for pancreatic and gastric cancers [11, 146] . The induction of sialyl-Le a/x is caused by alteration of glycosyltransferases and sugar transporter gene expression, which may be mediated by hypoxic conditions [76] .
As far as we know, there are no studies that associated other Tumor-Associated Carbohydrate Antigens (TACA), such as T, Tn, and Lewis b/y antigens, to intratumoral hypoxia.
Alterations in the Cell-Cell and Cell-Extracellular Matrix Interactions Under Hypoxia
Proteoglycans (PGs) are macromolecules composed of a core protein chain with one or more glycosaminoglycan (GAGs) covalently attached to the protein structure. GAGs are polysaccharides formed by repetitions of negatively charged disaccharides. They are usually [147] . Regarding to PGs' location, when they are produced intracellularly can be kept in secretory vesicles to regulate the viability of certain enzymes. They can be inserted into the plasma membrane to interact with receptors and ligands, inside or outside the cell, such as syndecans and glypicans. Finally, they can be released into the extracellular matrix (ECM), among which may be mentioned perlecans, biglycans, aggrecans and decorins [148, 149] . The variety of GAGs that may be attached to PGs confers a molecular complexity, which directly reflects possible interactions that these macromolecules can participate in.
Among CSPGs, there are small leucine-rich proteoglycans (SLRPs), which are composed primarily of leucine-rich repeats. They are significantly present in ECM and are capable of stabilizing collagen fibers and promoting cellular growth, apoptosis, and tissue remodeling [150] . Neurocan is an SLRP expressed in the central nervous system during the late embryonic phase. This PG participates in a critical step of this system's development, controlling neuronal growth through inhibition of neurite outgrowth [151] . Perlecan, agrin, and collagen type XVIII are examples of some PGs with structural functions at the basement membrane, an organized layer of the ECM [152] [153] [154] .
Syndecan family members are intramembranous and have a cytoplasmic tail, participating in signal transmission from the extracellular environment to the cytoplasm [155, 156] . Heparan sulfate is closely associated to the differentiation process of stem cells; embryonic stem cells derived from knockout mice of EXT1 (exostosin glycosyltransferase 1), a gene responsible for HSPG synthesis, did not differentiate, except when it was post-treated with heparin [157] . Others types of PGs have essential roles in the specific tissues in which they are localized, but their functions are related to crucial processes, such as homeostasis, development, repair, and disease, especially in tumor conditions [147] .
Cancer cells, through different cell-cell and cell-ECM interactions, promote alterations in the tumor microenvironment in order to favor proliferation, development, and potential invasion of distant tissues [158, 159] . Among modifications in ECM composition, the majority occurs through PGs glycosylation, either enhancing or decreasing the expression of some of these molecules, such as syndecans, or inhibiting the production of others [6, [160] [161] [162] . The association between hypoxia and tumor progression is also correlated with alterations in ECM composition through HIF-1α control of the glycosylation process [163] [164] [165] .
It is known that a hypoxic condition, in the cancer context, promotes the recruitment of macrophages to growing tissue [166] [167] [168] . Asplund et al. noticed that hypoxia, combined with enzymatic removal of HSPGs chains, increased the motility of macrophages more than hypoxia per se. Hypoxia reduced the expression of syndecans-1 and -4, and inhibited the expression of EXT1 and EXT2 enzymes, both known to be tumor suppressor genes and related to HSPG synthesis [169] .
Versican, a CSPG from the aggrecan family, is the most common PG in ECM, involved in cell adhesion, proliferation, and migration under healthy conditions [170] [171] [172] . It is known that the versican produced by mononuclear cells participates in the process of blood vessel formation, suggesting that this molecule may promote angiogenesis and tumorigenesis [173] . However, in hypoxia, versican has its specific production by macrophages upregulated, even more so after a long exposure (five days) as opposed to only one day [174] . These cells are over-recruited in hypoxic areas, and remain there for long periods of time. Studies involving macrophages and hypoxic conditions showed how tumor cells and their microenvironment could manipulate, directly and indirectly, many different mechanisms to favor its own development and growth.
On the other hand, Koike et al. focused on investigating the possible effects of HIF control on carbohydrate determinants. Human colon cancer cells lines (SW480, C-1, and Colo201 lineages) were used to understand the relationship between PGs and cell-adhesion molecules. The authors reported that hypoxic conditions increased syndecan-4 and α5-integrin gene expression. Both macromolecules are involved in cellular migration and celladhesion processes, especially in the enhanced adhesion of cancer cells to fibronectin, which [84] . Lumican is a member of the SLRP family and can regulate diverse essential processes, such as cell proliferation, adhesion, and invasion, and is critical to control tumor progression and development [175] . Its expression, both positive and negative, has been associated with tumor growth, depending on the tissue [176] [177] [178] [179] . In a clinical study, 131 patients with pancreatic ductal adenocarcinoma (PDAC) tumors were selected in order to correlate lumican expression and the tumor progression. Primary PDAC cells and recombinant human lumican protein were used to simulate in vivo interactions between stromal lumican and PDAC cells. The study showed that patients who had PG localized mostly in the stromal rather than the epithelial area also presented a decrease in metastatic recurrence. In vivo model showed that lumican decreased EGFR (epidermal growth factor receptor) and HIF-1α expression via Akt; cancer cells with enhanced HIF-1α activity became resistant to lumican-induced inhibition of glucose consumption and apoptosis [180] . Therefore, lumican acts against pancreatic cancer cell development, protecting the microenvironment from the consequences of HIF-1α, and is correlated with tumor progression.
Decorin, another PG from the SLRP family, has an important role in ECM protection and in the inhibition of tumor progression, mainly by disfavoring angiogenesis [181, 182] . Neill et al. reported that decorin reduced HIF-1α in a breast cancer in vitro model (MDA-MB-231 lineage), as well as VEGFA, both in normoxic conditions, performing an important role against tumor growth [183] . In the hypoxia context, decorin protected glioblastoma cells, both in vitro and in vivo, against oxygen and glucose deprivation situations. It was observed that an overexpression of p21, p27 (both tumor suppressor genes), and Ras mRNA levels, and induction and activation of Akt at the protein level, were unusual under normoxic conditions [184] . Ras enhancement is directly related to PI3K (Phosphoinositide 3-Kinase) interactions, and, consequently, Akt activation, resulting in protection against apoptosis [185] . Inhibition of hypoxia-induced death suggests that decorin could be essential in increasing the sensitivity of cells for anticancer therapy.
Integrins are a specific type of glycoproteins present on cell surfaces, which can bind to PGs in ECM, with cardinal roles in tumor progression. Under hypoxic conditions in a glioma model (U251 lineage), inhibition of αvβ3 integrin decreased focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (Pyk2) phosphorylation, which are associated with cell migration and invasion [186] .
Integrin-linked kinases are usually overexpressed in colorectal cancer patients and are associated with tumor survival and invasion under hypoxic conditions [187] . In human epithelial carcinoma (A431), Ren et al. reported that hypoxia-induced alterations to the glycosylation of ITGA3 prevented its efficient translocation to the plasma membran. This resulted in an enhanced invasive competence to cancer cells [97] . In another indirect correlation between PGs, integrins, and hypoxia, You et al. showed that pericyte expression of NG2 (neuron glia antigen-2) is critical for its interaction with endothelial cells in a NG2 knockdown melanoma (B16F10 lineage) model. Knockdown of NG2 caused several structural deficits in blood vessels in intracranial B16F10 melanomas, and, consequently, intratumoral hypoxia. This event was associated with the loss of β1 integrin activation in endothelial cells, suggesting a potential role of NG2 against hypoxia [188] .
It was observed that some PGs may inhibit tumor progression, such as decorin, while others have pro-tumor activity, such as versican. Others, such as lumican, depending on the cancer tissue, can promote or delay the development of cancer. HIF-1α can control some cellular processes through up-or downregulation of PGs and integrins (Fig. 6 ). For example, HIF-1α controls cell adhesion, inducing syndecan and integrins expression, favoring metastasis. Since glycomolecules, as lumican, can regulate the expression and activity of HIF-1α, pancreatic cancer cell proliferation was inhibited through HIF-1α downregulation. Studies concerning hypoxia and alterations in PGs and/or integrins, and the interactions between ECM and cancer cells, in order to understand how they can be used to develop new targets and tools against current resistance to chemotherapies, are still insufficient.
Hypoxia Alters Cell Location of Galectins And Interaction with their Ligands
Galectins are part of the vast family of lectins, with one conserved carbohydraterecognition domain (CRD) and an affinity for β-galactose-containing glycans [189] . Presently, 16 mammalian galectins have been identified, which can be divided into three groups: Prototype galectins (galectin-1, -2, -5, -7, -10, -11, -13, -14, -15, and -16), containing one CRD per subunit and that can bind non-covalently, forming homodimers; tandem-repeat galectins (galectin-4, -6, -8, -9, and -12), with two CRDs connected by a functional peptide; and one chimeric galectin-3, which contains a CRD and a proline-glycine-rich N-terminal domain. Of all these, two are murine (galectin-5 and -6) and two presents in ruminants (galectin-11 and -12) [190, 191] .
Since galectins can form dimers and oligomeric structures, their functions are based on complexes with carbohydrate formations, resulting in the accumulation of these multivalent glycoconjugates [192] . When present on the cell surface and the extracellular environment, these structures can activate signaling pathways by regulating membrane receptors, promoting cell-cell adhesion and cell-matrix processes [193] . The wide cellular distribution of galectins contributes to a functional variety of these proteins, which are essential in several physiological processes, such as homeostasis of T cells [194] .
However, galectins have been associated with many disease processes, most notably in cancer, contributing to a variety of events, such as transformation of cancer cells via oncogenic Ras protein [195, 196] . Moreover, as described, galectins promote cell adhesion, contributing to invasion and metastasis processes by tumor cells [191] .
Angiogenesis is an important process for the progression of hypoxic tumors [197, 198] . Gal-1, the first protein identified within the galectin family, shows involvement in tumor angiogenesis, and it was first suggested that both vascular smooth muscle and endothelial cells express the protein [199] . Gal-1 also modulates the expression of six other hypoxiarelated genes that are implicated in angiogenesis (i.e., CTGF, ATF3 (activating transcription factor 3), PPP1R15A (protein phosphate 1 regulatory subunity 15A), HSPA5 (heat shock protein family A member 5), TRA1 (transcription-associated protein 1) and CYR61 (cysteine rich angiogenic inducer 61) [200] . Clausse et al. have also previously shown that galectin-1 was upregulated in capillaries associated with carcinoma cells, and could mediate interactions between tumors and endothelial cells in vitro, suggesting a potential role for Gal-1 in modulating angiogenesis [201, 202] .
Lectin interactions with endogenous glycans control cell signaling and neovascularization [96, 203] and, therefore, can provide important information about hypoxic environments. When performing in vitro studies, Croci and Rabinovich (2014) observed that serum-free conditioned medium from an anti-VEGF refractory, but not anti-VEGF sensitive tumors, induced endothelial cell exposure of Gal-1-specific ligands. Large amounts of sialic acid α2,6 were found in tumor-associated vessels from mice inoculated with tumors that were sensitive to anti-VEGF (B16-F0 melanoma and CT26 colon carcinoma) in response to VEGF blockade, which prevented Gal-1 binding and angiogenesis [204] . In two studies, the author 
identified a compensatory mechanism in which the direct association of Gal-1 with complex N-glycans on VEGFR2 domains may substitute for the absence of VEGF-A to promote EC signaling and preserve the angiogenic phenotype. A hypoxic microenvironment influences the glycan profile of HUVEC EC, increasing essential glycans for Gal-1 binding, including β1-6GlcNAc-branched N-glycans and poly-LacNAc structures. Disruption of Gal1-N-glycan interactions promoted transient regularization of tumor-associated vasculature in vivo, and facilitated the influx of immune cells into the tumor microenvironment. This offers a novel alternative to evade resistance to VEGF-targeted therapies [85, 204] . Gal-1 can be found in the nucleus and the intracellular face of the cell membrane, but is mainly in cytoplasm, and is secreted by a non-canonical secretory pathway [205] . This protein has been known as a direct target of HIF-1α [206] .
Kaposi's sarcoma cells exhibit altered expression of Gal-1, which is directly induced by the presence of hypoxia and infection by human herpesvirus [204] . In head and neck carcinoma cell lines (FaDu), Gal-1 transcriptional levels were upregulated after 24 h of hypoxia treatment (<0.01% O 2 ) and Gal-1 post-translational and secreted levels were elevated in 12 h, under both 2% and 0.2% hypoxia. The inversely proportional relationship between Gal-1 and T cell markers in vivo suggests that hypoxia-induced upregulation of galectin-1 is essential to the immune system escape process [205] .
In a renal carcinoma cell line (CAK-1), Gal-1 expression increased proportionally with CoCl2 doses, which mimics a hypoxic environment by inhibiting the degradation of HIF-1α. Increased Gal-1 levels favor cell migration and promote phosphorylation of Akt, mTOR (mechanistic target of rapamycin), and p70 kinase, which are involved in proliferation, cell growth, and survival processes [206] .
There is an increasing number of studies that evaluate galectins-1 and -3 expressions in tumors associated with the central nervous system, especially gliomas and glioblastomas, in addition to hypoxic tumors [207] [208] [209] [210] . According to Le Mercier et al., Gal-1 expression is increased under hypoxic conditions. Partial blocking of Gal-1 expression by siRNA administration in Hs683 orthotopic xenografts in mouse brains reduced endoplasmic reticulum stress and enhanced the therapeutic benefits of temozolomide, a pro-autophagy drug [200] .
In a xenotransplant model of glioblastoma multiform, the accumulation of cells that express high levels of Gal-3 in specific hypoxic areas called pseudopalisades, regions around the necrotic tissue was observed. Additionally, in hybrid human/murine glioblastoma cell line (NG97ht) there were positive changes in the expression of Gal-3, dependent on HIF-1α and NF-kB, under conditions that mimic a hypoxic microenvironment with nutrient deprivation. Association of these glycoprotein levels with cell survival, evidenced by Gal-3 silencing, increased the relative amount of death in the same cell line [211] .
Gal-3 is the only galectin that belongs to the chimera subgroup. It is found in normal tissue and is highly expressed in many cancers [212] . Gal-3 is involved in cell growth, differentiation, adhesion, mRNA processing, and angiogenesis [213, 214] .
Gal-3 is present in many compartments of cancer cells, including cytoplasm, acting in apoptosis inhibition [215] ; in nucleus, regulating selective expression of some genes [216] ; secreted, allowing for cell adhesion; and interacting with ECM [217] . In a microarray study, Olbryt et al. identified more than 430 hypoxia-responsive genes, including Gal-3 and its ligand fibronectin 1, in murine melanoma cell line (B16-F10) in vitro. They are associated with melanoma, but have not been reported to be regulated by hypoxia in human melanoma cells [218] .
Gal-3 has been considered a tumor-associated antigen of malignancy level in breast cancer, and is implicated in aspects, such as angiogenesis [219] , adhesion [220] , invasion [221] , apoptosis inhibition [222] , migration [223] , and therapeutic resistance [224] . Chen et al., through hydrazide-based chemistry method combined with liquid chromatography tandem-mass spectrometry (LC-MS/MS), identified 72 unique N-linked glycoproteins that were significantly regulated in triple negative breast cancers, among which is LGALS3BP.
LGALS3BP is a highly-glycosylated galectin-3 binding protein whose bio-physiological activity is not yet well defined, but recent findings point to a possible involvement with cancer growth and progression [225] .
Immunohistochemical studies performed by our group showed that Gal-3 expression, in invasive and in situ ductal carcinoma of breast, was significantly higher among those with hypoxic regions. We also observed that Gal-1 expression was found mainly in the extracellular matrix and tumor-associated stromal cells, demonstrating their importance in the relationship between a tumor and its microenvironment [226, 227] .
The amount of studies with galectins and hypoxic microenvironments in cancer demonstrates the key role of these glycan-binding proteins for tumor development and progression (Fig. 7) . Galectins, mainly gal-1 and -3, may be actively participating in the molecular machinery needed for cancer maintenance and are important targets for therapeutic research, as possible factors for cancer diagnoses, prognosis, and treatment.
O-Glcnacylation Regulates Cell Survival Under Hypoxic Conditions
O-GlcNAcylation is an important post-translational modification involved in regulating gene transcription, cellular signaling, and stress response under normal conditions. It occurs exclusively in the cytoplasm/nucleus, and is more similar to phosphorylation than to conventional glycosylation. Aberrant O-GlcNAcylation in cancer regulates glycolysis and reroutes metabolism pathways for cell survival and proliferation, and are involved invasion and metastasis processes [228, 229] .
A study performed by Ferrer and collaborators showed that O-GlcNAcylation is increased in breast cancer cells MDA-MB-231 cultured under hypoxic conditions (1% O 2 ). This process is responsible for regulating survival stress signaling via regulation of HIF-1α protein stability and degradation. Moreover, elevation of O-GlcNAcylation and O-GlcNAc transferase (the enzyme that catalyzes the transfer of the GlcNAc moiety to Ser/Thr residues) is associated with the expression of HIF-1 transcriptional targets that directly regulate glucose metabolism [230] .
In PK4A mouse pancreatic cancer cells, it was observed that there was a 40% increase of O-GlcNAcylation protein levels in hypoxia when compared to normoxia. Cells cultured in glucose-free media, in addition to GlcNAc metabolite, increased the amount of O-GlcNAc protein from 86% (normoxia) to 150% (hypoxia). In PK4A cells, and in vivo mouse model, transcripts of enzymes involved in O-GlcNAcylation processes, such as O-GlcNAc transferase and O-GlcNAcase, are upregulated under hypoxic conditions. Taken together, these results indicate that O-GlcNAcylation of proteins is dependent on glucose and glutamine availability, and is required for hypoxic pancreatic cancer survival [96] . O-GlcNAcylation also plays an important role in the metabolism regulation of lung cancer. In non-small cell lung carcinoma (H1299), hypoxia induces O-GlcNAcylation at serine 529 of PFK1 (6-Phosphoructokinase 1), an important enzyme of the glycolytic pathway, decreasing its activity. PFK1 O-GlcNAcylation redirects most of the glucose flux through the PPP and increases biosynthetic precursors, promoting cancer cell survival [231] . Rao et al. showed that O-GlcNAcylation of G6PD is upregulated in primary human lung cancer tissue samples, and in A549 lung cancer cells. Under hypoxic conditions (1% O 2 ), O-GlcNAcylation of G6PD in A549 cells induces upregulation in PPP flux, promoting the production of precursors involved in nucleotide biosynthesis and cell proliferation. Thus, modulation of PFK1 and G6PD glycosylation may provide new strategies for lung cancer therapy [41] .
Conclusion and Perspectives
Several therapeutic strategies for cancer has been studied and developed by researchers from around the world. Among the main ones stands out the inhibition / silencing of galectins and other carbohydrate binding proteins, the use of combination therapy, the improvement of drug delivery by nanostructures, and the use of hypoxia-activated drugs.
Galectins are the most well studied tumor-associated carbohydrate binding proteins and so many techniques have been implemented to promote the blockage of galectin activity in cancer [232] . Inhibition of galectin expression, using siRNA or antisense sequences, showed significant results in colon [233] , ovarian [234] , esophageal [235] , hepatocarcinoma [236] , glioma [237] , glioblastoma [238] , and melanoma [239] cell lines. Anti-galectin mAbs and Gal-3 recombinant were also effective in vitro studies with diverse cell lines [240] [241] [242] . Other galectin inhibition methods that showed some success including inhibition of biosynthesis of tumor-associated antigens [243] , use of modified citrus pectin (MCP) [244] , small carbohydrate-based inhibitors, such as ß-galactosides [245] , and multivalent and allosteric inhibitors, among others [232] .
Because its importance in maintaining tumor energy metabolism, glycolysis is also considered a field of therapeutic opportunities. Glucose analog 2-DG was used in patients for the first time in the 1950s and has been the most widely-investigated therapeutic agent in cancer glycolysis. However, since then, 2-DG has been ineffective in reducing tumor growth and another anti-glycolytic agent, such as Lonidamin, similarly failed to show efficacy in several cancers [246, 247] .
More drugs and glycoproteins have emerged as possible alternative therapeutic targets for cancer. Tamoxifen, an endocrine therapy drug used to treat estrogen-receptor-positive breast cancer, is already used in the clinic and has been demonstrating that part of its activity may be linked to its "power" to modulate glycomolecules. This drug has a significant number of effects, including inhibition of sphingolipid metabolism through the impediment of ceramide glycosylation [248] .
Other strategy is the combination of two or more therapeutic agents, Pusapati et al. found that simultaneous inhibition of glycolysis and mTORC1 signaling prevented in vitro and in vivo tumor cell growth. Once activated, mTORC1 directs the increase of glucose flux via the pentose phosphate pathway back into glycolysis, avoiding the glycolysis block and ensuring adequate ATP production. These findings reveal the important benefits of possible therapeutic improvement by targeting the Warburg effect [249] .
Glycosylation of nanoparticles (NP) has also been utilized to target and deliver therapeutic drugs to malignant cells, and some TACA constitute potential targets for vaccine design. Still, one of the greatest obstacles in developing anticancer vaccines lies in choosing the right antigen, given inter and intratumor heterogeneity, and the fact that some carbohydrate antigens may also be present in normal tissues [250] . Recently, there has been a growing amount of research that looks for solutions to this problem, illustrating the possibility of targeting, silencing, and/or monitoring galectin or glycan expression using NP-based platforms [251] [252] [253] [254] [255] [256] .
In addition to the "glyco" component, tumor microenvironment characteristics should be considered for the selection and development of new drugs and therapeutic approaches. Hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells, such as the mTOR and UPR (unfolded protein response) pathways, are current strategies proposed for targeting hypoxic tumor cells [22] . Among the hypoxia-activated prodrugs that have been developed are TH-302 (Evofosfamide) [257] , EO9 (Apaziquone) [258] , and Tirapazamine (TPZ) [259] . However, there are no studies analyzing glycan processing inhibition and hypoxic sensitizers as a synergistic strategy to treat cancer cells. This therapeutic strategy seems to be promising and should be investigated by glycobiology and oncology researchers.
Aberrant glycosylation has presently emerged as a major hallmark of cancer. It has been elucidated that ligand-receptor interactions involving carbohydrates are modified by tumor microenvironment conditions, such as hypoxia. There is a need for more extensive characterization of glycosylation changes associated with carcinogenesis in order to identify novel biomarkers, mainly in the context of hypoxia. Furthermore, this needs to be accompanied by a better understanding of the basis of these changes and their relation to cancer phenotypes.
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